Tags

Type your tag names separated by a space and hit enter

Conjugation of ovalbumin to trimethyl chitosan improves immunogenicity of the antigen.
J Control Release. 2010 Apr 19; 143(2):207-14.JC

Abstract

Subunit vaccines are generally safer, but often less effective than live attenuated vaccines as they lack the necessary co-stimulatory factors. The formulation of an adjuvant like N-trimethyl chitosan (TMC) with an antigen can overcome its poor immunogenicity. Recent data suggest the importance of incorporating the antigen and the adjuvant into one entity for maximum immunostimulatory effect, e.g. by using (nano)particles. In the present paper we introduce the conjugation of an antigen, ovalbumin (OVA), to TMC as an alternative to nanoparticles for subunit vaccination. OVA was covalently linked to TMC using thiol chemistry (SPDP method). The uptake of the resulting TMC-OVA conjugate by dendritic cells (DC) and its effect on DC maturation was assessed in vitro and its immunogenicity was investigated in mice. We found that with the SPDP method a reducible covalent bond between TMC and OVA could be introduced, without disrupting the protein's antigenicity and structure. Uptake of TMC-OVA conjugate by dendritic cells was similar to the uptake of TMC/OVA nanoparticles, over 5-fold increased compared to a solution of OVA and TMC. Mice immunized with TMC-OVA conjugate produced 1000-fold higher OVA specific IgG titers than mice immunized with either OVA or a physical mixture of TMC and OVA. Moreover, these antibody titers were slightly elevated compared to the titers obtained with TMC/OVA nanoparticles. Conjugation of the antigen to an adjuvant is therefore a viable strategy to increase the immunogenicity of subunit vaccines and may provide an alternative to the use of particles.

Authors+Show Affiliations

Division of Drug Delivery Technology, Leiden/Amsterdam Center for Drug Research, Einsteinweg 55, 2333 CC Leiden, The Netherlands.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

20074597

Citation

Slütter, Bram, et al. "Conjugation of Ovalbumin to Trimethyl Chitosan Improves Immunogenicity of the Antigen." Journal of Controlled Release : Official Journal of the Controlled Release Society, vol. 143, no. 2, 2010, pp. 207-14.
Slütter B, Soema PC, Ding Z, et al. Conjugation of ovalbumin to trimethyl chitosan improves immunogenicity of the antigen. J Control Release. 2010;143(2):207-14.
Slütter, B., Soema, P. C., Ding, Z., Verheul, R., Hennink, W., & Jiskoot, W. (2010). Conjugation of ovalbumin to trimethyl chitosan improves immunogenicity of the antigen. Journal of Controlled Release : Official Journal of the Controlled Release Society, 143(2), 207-14. https://doi.org/10.1016/j.jconrel.2010.01.007
Slütter B, et al. Conjugation of Ovalbumin to Trimethyl Chitosan Improves Immunogenicity of the Antigen. J Control Release. 2010 Apr 19;143(2):207-14. PubMed PMID: 20074597.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Conjugation of ovalbumin to trimethyl chitosan improves immunogenicity of the antigen. AU - Slütter,Bram, AU - Soema,Peter Christiaan, AU - Ding,Zhi, AU - Verheul,Rolf, AU - Hennink,Wim, AU - Jiskoot,Wim, Y1 - 2010/01/13/ PY - 2009/11/24/received PY - 2009/12/18/revised PY - 2010/01/04/accepted PY - 2010/1/16/entrez PY - 2010/1/16/pubmed PY - 2010/7/2/medline SP - 207 EP - 14 JF - Journal of controlled release : official journal of the Controlled Release Society JO - J Control Release VL - 143 IS - 2 N2 - Subunit vaccines are generally safer, but often less effective than live attenuated vaccines as they lack the necessary co-stimulatory factors. The formulation of an adjuvant like N-trimethyl chitosan (TMC) with an antigen can overcome its poor immunogenicity. Recent data suggest the importance of incorporating the antigen and the adjuvant into one entity for maximum immunostimulatory effect, e.g. by using (nano)particles. In the present paper we introduce the conjugation of an antigen, ovalbumin (OVA), to TMC as an alternative to nanoparticles for subunit vaccination. OVA was covalently linked to TMC using thiol chemistry (SPDP method). The uptake of the resulting TMC-OVA conjugate by dendritic cells (DC) and its effect on DC maturation was assessed in vitro and its immunogenicity was investigated in mice. We found that with the SPDP method a reducible covalent bond between TMC and OVA could be introduced, without disrupting the protein's antigenicity and structure. Uptake of TMC-OVA conjugate by dendritic cells was similar to the uptake of TMC/OVA nanoparticles, over 5-fold increased compared to a solution of OVA and TMC. Mice immunized with TMC-OVA conjugate produced 1000-fold higher OVA specific IgG titers than mice immunized with either OVA or a physical mixture of TMC and OVA. Moreover, these antibody titers were slightly elevated compared to the titers obtained with TMC/OVA nanoparticles. Conjugation of the antigen to an adjuvant is therefore a viable strategy to increase the immunogenicity of subunit vaccines and may provide an alternative to the use of particles. SN - 1873-4995 UR - https://www.unboundmedicine.com/medline/citation/20074597/Conjugation_of_ovalbumin_to_trimethyl_chitosan_improves_immunogenicity_of_the_antigen_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0168-3659(10)00016-7 DB - PRIME DP - Unbound Medicine ER -